CXCL13: a common target for immune-mediated inflammatory diseases.

IF 3.2 4区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Clinical and Experimental Medicine Pub Date : 2024-10-24 DOI:10.1007/s10238-024-01508-8

Lu Hui, Ye Li, Meng-Ke Huang, Yong-Mei Jiang, Ting Liu

{"title":"CXCL13: a common target for immune-mediated inflammatory diseases.","authors":"Lu Hui, Ye Li, Meng-Ke Huang, Yong-Mei Jiang, Ting Liu","doi":"10.1007/s10238-024-01508-8","DOIUrl":null,"url":null,"abstract":"<p><p>CXCL13 is a chemokine that plays an important role in the regulation and development of secondary lymphoid organs. CXCL13 is also involved in the regulation of pathological processes, particularly inflammatory responses, of many diseases. The function of CXCL13 varies depending on the condition of the host. In a healthy condition, CXCL13 is mainly secreted by mouse stromal cells or human follicular helper T cells, whereas in diseases conditions, they are produced by human peripheral helper T cells and macrophages in non-lymphoid tissues; this is termed ectopic expression of CXCL13. Ectopic CXCL13 expression is involved in the pathogenesis of various immune-mediated inflammatory diseases as it regulates the migration of B lymphocytes, T lymphocytes, and other immune cells in inflammatory sites as well as influences the expression of inflammatory factors. Additionally, ectopic expression of CXCL13 plays a key role in ectopic lymphoid organ formation. In this review, we focused on the sources of CXCL13 in different conditions and its regulatory mechanisms in immune-mediated inflammatory diseases, providing novel ideas for further research on targeting CXCL13 for the treatment of immune-mediated inflammatory diseases.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"24 1","pages":"244"},"PeriodicalIF":3.2000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499446/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10238-024-01508-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

CXCL13 is a chemokine that plays an important role in the regulation and development of secondary lymphoid organs. CXCL13 is also involved in the regulation of pathological processes, particularly inflammatory responses, of many diseases. The function of CXCL13 varies depending on the condition of the host. In a healthy condition, CXCL13 is mainly secreted by mouse stromal cells or human follicular helper T cells, whereas in diseases conditions, they are produced by human peripheral helper T cells and macrophages in non-lymphoid tissues; this is termed ectopic expression of CXCL13. Ectopic CXCL13 expression is involved in the pathogenesis of various immune-mediated inflammatory diseases as it regulates the migration of B lymphocytes, T lymphocytes, and other immune cells in inflammatory sites as well as influences the expression of inflammatory factors. Additionally, ectopic expression of CXCL13 plays a key role in ectopic lymphoid organ formation. In this review, we focused on the sources of CXCL13 in different conditions and its regulatory mechanisms in immune-mediated inflammatory diseases, providing novel ideas for further research on targeting CXCL13 for the treatment of immune-mediated inflammatory diseases.

查看原文本刊更多论文

CXCL13：免疫介导的炎症性疾病的共同靶点。

CXCL13 是一种趋化因子，在次级淋巴器官的调节和发育中发挥着重要作用。CXCL13 还参与调节许多疾病的病理过程，特别是炎症反应。CXCL13 的功能因宿主的状况而异。在健康状态下，CXCL13 主要由小鼠基质细胞或人类滤泡辅助性 T 细胞分泌，而在疾病状态下，则由人类外周辅助性 T 细胞和非淋巴组织中的巨噬细胞产生；这被称为 CXCL13 的异位表达。CXCL13 的异位表达与各种免疫介导的炎症性疾病的发病机制有关，因为它能调节 B 淋巴细胞、T 淋巴细胞和其他免疫细胞在炎症部位的迁移，并影响炎症因子的表达。此外，CXCL13 的异位表达在异位淋巴器官的形成中起着关键作用。在这篇综述中，我们重点探讨了CXCL13在不同情况下的来源及其在免疫介导的炎症性疾病中的调控机制，为进一步研究以CXCL13为靶点治疗免疫介导的炎症性疾病提供了新思路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Medicine 医学-医学：研究与实验

CiteScore

4.80

自引率

2.20%

发文量

159

审稿时长

2.5 months

期刊介绍： Clinical and Experimental Medicine (CEM) is a multidisciplinary journal that aims to be a forum of scientific excellence and information exchange in relation to the basic and clinical features of the following fields: hematology, onco-hematology, oncology, virology, immunology, and rheumatology. The journal publishes reviews and editorials, experimental and preclinical studies, translational research, prospectively designed clinical trials, and epidemiological studies. Papers containing new clinical or experimental data that are likely to contribute to changes in clinical practice or the way in which a disease is thought about will be given priority due to their immediate importance. Case reports will be accepted on an exceptional basis only, and their submission is discouraged. The major criteria for publication are clarity, scientific soundness, and advances in knowledge. In compliance with the overwhelmingly prevailing request by the international scientific community, and with respect for eco-compatibility issues, CEM is now published exclusively online.